



Primary malignant chest wall tumors: surgical management and factors predicting survival

Alice Bellini¹, Pia Ferrigno¹, Giovanni Maria Comacchio¹, Sara Rossi¹, Giorgio Cannone¹, Ivan Lomangino¹, Giuseppe Bellofiore¹, Marco Mammana¹, Giulia Lorenzoni², Danila Azzolina^{2,3}, Dario Gregori², Andrea Zuin¹, Andrea Dell'Amore¹, Federico Rea¹

¹Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Thoracic Surgery Unit, University of Padova, Padova, Italy; ²Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, Italy; ³Department of Translational Medicine, University of Piemonte Orientale, Vercelli, Italy

Contributions: (I) Conception and design: A Bellini, A Dell'Amore, G Comacchio, F Rea; (II) Administrative support: A Bellini, A Dell'Amore, P Ferrigno; (III) Provision of study materials or patients: A Bellini, A Dell'Amore, P Ferrigno, S Rossi, G Cannone, G Bellofiore, I Lomangino; (IV) Collection and assembly of data: A Bellini, A Dell'Amore, P Ferrigno, S Rossi, G Cannone, G Bellofiore, I Lomangino; (V) Data analysis and interpretation: A Bellini, A Dell'Amore, G Comacchio, G Lorenzoni, D Azzolina, D Gregori, F Rea; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Andrea Dell'Amore. Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Thoracic Surgery Unit, University of Padova, via Giustiniani 2, 35128 Padova, Italy. Email dellamore76@libero.it.

Background: Primary malignant chest wall tumors (PMCWTs) are a rare heterogeneous group of neoplasms arising from bones and soft tissues of the thorax. The gold standard treatment is surgical resection. In case of wide chest wall defects, there are two possibilities of reconstruction: prosthetic or biological mesh and/or tissue flaps. The aim of this study is to analyze different factors concurring to the outcome of patients with PMCWTs surgically treated in our Institution.

Methods: Retrospective study of 52 patients treated for PMCWTs from 1982 to 2019. Survival, recurrence and postoperative morbidity were considered as outcomes. Age, sex, type of resection, neo- and adjuvant treatments, side, size, number of resected ribs, prosthetic reconstruction and histological type were analyzed as possible prognostic factors.

Results: There were 28 males (53.8%) and 24 females (46.2%), with a median age of 58 years (range, 21–85 years). Chondro-osseous subtypes were the most represented (46.2%). Tumor involved the sternum in 17 cases (32.7%). Resection with reconstruction was performed in 31 (59.6%). Prosthesis alone were utilized in 16 cases (51.6%). Eleven patients developed post-operative morbidity. Median maximum diameter of the tumor was 7 cm (range, 1.9–30 cm). The 1-, 3-, 5-, and 10-year survival rates were 83.3%, 69.9%, 51.5% and 45.6%, respectively, while the median OS was 45 months. Predictors of better OS were no prosthetic reconstruction (HR 0.25, 95% CI: 0.09–0.71, P=0.009) and chondro-osseous tumor histological type (HR 0.34, 95% CI: 0.13–0.87, P=0.02). Recurrences occurred in 13 patients and the pattern for the relapse was local in 7 patients and distant in 5.

Conclusions: A careful pre-operative selection of fit patients, especially in chondro-osseous subtype without prosthetic reconstruction leads to good survival outcomes with acceptable morbidity.

Keywords: Chest wall tumor; sternal tumor; reconstruction; prosthesis; muscle flap

Received: 04 November 2019; Accepted: 13 November 2019; Published: 13 December 2019.

doi: 10.21037/ccts.2019.11.08

View this article at: <http://dx.doi.org/10.21037/ccts.2019.11.08>

Introduction

Primary malignant chest wall tumors (PMCWTs) are a heterogeneous group of neoplasms arising from bones and soft tissues of the thorax (1,2). These tumors are rare, representing less than 1% of all primary malignant tumors (2). Most PMCWTs are sarcomas (3), categorized according to the 4th edition of World Health Organization (WHO) Classification (4). Among sarcomas, chondrosarcoma is the most common primary malignancy of the chest wall (5). According to the literature, the most important factor affecting survival is complete resection of the tumor (1), hence the goal of surgery is wide resection with free margins of normal tissue, in order to prevent local recurrence. In case of wide excision causing extensive chest wall defects, both bony reconstruction and soft tissue coverage are indispensable (6-8). In this scenario, there are two possibilities to cover the chest wall defect: prosthetic or biological (allo- or homograft) mesh and/or tissue flaps (8-13). The aim of this study is to analyze different factors concurring to the outcome of patients with PMCWTs surgically treated in our Institution.

Methods

Between April 1982 and July 2019, 52 patients were surgically treated for PMCWTs at Padua University Hospital. Other types of chest wall tumors (benign or metastatic) were excluded from this retrospective study. The present study obtained ethics approval from the institutional review board of Padua University Hospital (PD00-19-03CT). Written informed consent was achieved from the patients for publication of this manuscript and any accompanying images.

PMCWTs were classified, according to the 4th edition of World Health Organization (WHO) Classification of sarcomatous tumors of soft tissue and bone (4), into the following groups: (I) adipocytic tumors, (II) fibroblastic/myofibroblastic tumors, (III) fibrohistiocytic tumors, (IV) smooth muscle tumors, (V) skeletal muscle tumors, (VI) vascular tumors, (VII) perivascular tumors, (VIII) chondro-osseous tumors, (IX) neuroectodermal tumors, (X) tumors of uncertain differentiation. Non sarcomatous PMCWTs were classified as “others”. In addition, PMCWTs were categorized, based on their tissue of origin, into 3 groups (2): (I) bony sarcomas, as osteosarcoma, chondrosarcoma and PNET/Ewing’s sarcoma, (II) soft tissue sarcomas, as liposarcoma, fibromatosis/fibrosarcoma, malignant fibrous

histiocytoma, leiomyosarcoma, rhabdomyosarcoma, angiosarcoma, synovial sarcoma, malignant giant cells tumor, malignant PEC-oma and malignant ossifying fibromyxoid tumor, (III) others, as solitary plasmocitoma. Primitive sarcomas of the chest wall, according to the cancer cell differentiation, were grouped as G1 (low-grade sarcoma), G2 (intermediate-grade sarcoma) or G3 (high-grade sarcoma). Hospital records of the patients were reviewed and collected into a retrospective database. All relevant preoperative, intraoperative and postoperative variables were analyzed in order to identify possible prognostic factors. Follow-up information was obtained from clinical visit, imaging studies and phone interview. Descriptive statistics were reported as median for continuous variables and percentage for categorical variables. A Cox-Proportional Hazard model was estimated to assess the effect of covariates on patients’ survival. The relevant predictors were selected with a subset regression approach using the Bayes Information Criterion (BIC). Analyses were performed using R system (14) with the packages rms, survival (15), and gmulti (16). Results were considered significant if the P value was less than 0.05. Overall survival (OS) was calculated from the date of surgical resection to the date of death or last follow up. Survival functions was estimated using the Kaplan-Meier estimator.

Results

Patients characteristic

Fifty-two patients underwent surgical resection of PMCWTs during the study period. Patient characteristics and type of surgical procedure are summarized in *Table 1*. There were 28 (53.8%) males and 24 (46.2%) females with a median age at time of surgery of 58 years (range, 21–85 years). Tumor was right-sided in 16 (30.8%) patients, left-sided in 19 (36.5%) and involved the sternum in 17 (32.7%). Isolated resection of the lesion without need of chest wall reconstruction was performed in 21 patients (40.4%), while reconstruction was necessary in 31 cases (59.6%). Prosthesis alone were utilized in 16 cases (51.6%), muscle flaps alone in 3 (9.7%) and both in 12 (38.7%). Flaps utilized were pectoralis major muscle in 10 patients, latissimus dorsi in 3, rectus abdominis in 1 and omentoplasty in 2. Non absorbable synthetic prosthesis were used in 21 cases (11 polytetrafluoroethylene and 10 polypropylene), while absorbable one in 1 (polyglactin). In 11 cases titanium

Table 1 Patients characteristics (N=52)

Patients characteristics	n (%)
Gender	
Male	28 (53.8)
Female	24 (46.2)
Median age, years (range)	58 (21–85)
Side	
Right	16 (30.8)
Left	19 (36.5)
Sternum	17 (32.7)
Type of surgery	
Isolated resection	21 (40.4)
Resection with reconstruction	31 (59.6)
Type of reconstruction	
Muscle flaps alone	3 (9.7)
Prosthesis alone	16 (51.6)
Both	12 (38.7)
Resection	
R0	36 (69.2)
R1	3 (5.8)
R2	9 (17.3)
NR	4 (7.7)
Median tumour size, cm (range)	7 (1.9–30)
Neoadjuvant treatment	7 (13.5)
Adjuvant treatment	10 (19.2)

plates were utilized, 9 of which in case of sternal allografts. Cadaveric sternal allograft was employed in 9 patients. Ribs were resected in 31 cases (59.6%) with a median number of resected ribs of 2 (range, 1–9), while clavicle in 3 cases (5.8%). Oncological complete resection (R0) was achieved in 36 patients (69.2%), whereas resection with microscopic (R1) and macroscopic (R2) residual tumor in 3 (5.8%) and 9 (17.3%) respectively and it was not reported in 4 cases (7.7%). Pathological examination showed sarcomatous disease in 48 patients (92.3%) and plasmocitoma in 4 (7.7%). In particular, there were 29 cases of bony sarcomas and 19 of soft tissue ones. Chondrosarcoma were the most frequent. Histological types are resumed in *Table 2*. Median maximum diameter of the neoplasm was 7 cm (range, 1.9–30 cm).

Neoadjuvant and adjuvant therapy was administrated in 7 (13.5%) and 10 (19.2%) patients, respectively.

Perioperative and postoperative complications

Data about complications were not available for 9 patients; of the remaining 43 patients, early post-operative complications occurred in 11 cases (25.6%): anemia requiring blood transfusion in 3 cases, atrial fibrillation treated with electrical cardioversion in 1, bilateral pneumonia in 1, empyema surgically treated with open window thoracostomy in 1, pneumothorax in 1, hyperpyrexia in 1, neuropathic pain in 1, chronic cutaneous fistula in 1, and wound dehiscence surgically treated in 1. Of the 11 patient experiencing complications, 10 underwent prosthetic reconstruction and particularly 6 had sternal reconstruction. No perioperative mortality was observed.

OS

Follow up was completed in all the patients, with a median of 42 months (range, 0–421 months). OS at 1-, 3-, 5- and 10-year were 83.3%, 69.9%, 51.5% and 45.6%, respectively, while the median OS was 45 months (*Figure 1*). At multivariate analysis predictors of better OS were no need of prosthetic reconstruction (HR 0.25, 95% CI: 0.09–0.71, P=0.009) and chondro-osseous tumor histological type (HR 0.34, 95% CI: 0.13–0.87, P=0.02). Age, sex, type of resection (R0 *vs.* R1+R2), neo- and adjuvant treatments, side (involving sternum *vs.* others), size and number of resected ribs were not statistically significant.

Recurrence

Data about recurrence were not available for 16 patients, hence an analysis about predictors of worse disease-free survival was not possible. Of the remaining 36 patients, 13 experienced relapses. The recurrence pattern for the first relapse was: local relapse in 7 patients, distant in 5 patients and unknown in 1 case. Among these 13 patients with recurrence, 7 underwent redo-surgery alone, 1 underwent chemotherapy alone, 1 underwent radiotherapy alone and in 4 the treatment was unknown. Four patients experienced a second recurrence and 3 of them had a third relapse.

Discussion

PMCWTs are rare tumors, challenging both to diagnose

Table 2 Histological features (N=52)

Histological features	n (%)
Histology	
Sarcoma	48 (92.3)
Chondrosarcoma	22
G1	8
G2	10
G3	3
Fibromatosis	3
PNET/Ewing's sarcoma	3/1
Fibrosarcoma	2
Malignant fibrous histiocytoma	2
Leiomyosarcoma	2
Osteosarcoma	2
Synovial sarcoma	2
Others	9
Plasmocitoma	4 (7.0)
Tissue groups	
Bony sarcoma	29 (55.8)
Soft tissue sarcoma	19 (36.5)
Others (plasmocitoma)	4 (7.7)
4th WHO classification of sarcoma	
Adypocitic	1
Fibroblastic/myofibroblastic	5
Fibrohistiocytic	3
Smooth muscle	2
Skeletal muscle	1
Vascular	1
Perivascular	0
Chondro-osseous	24
Neuroectodermal	4
Uncertain differentiation	4
NR*	3
Cancer cell sarcoma differentiation**	
Low-grade	9
Intermediate-grade	10
High-grade	19
NR	7

*, unspecified myosarcoma, cordoma and granulocytic sarcoma; **, 3 cases of fibromatosis not included.




Figure 1 Kaplan-Meier survival curve showing OS of the whole population (N=52).

and treat. Major series presented over the literature are summarized in *Table 3*. Surgical resection is the gold standard treatment for these neoplasms, exceptions include the “medical tumors”: Ewing sarcoma family of tumors, and solitary plasmocitoma (usually associated to latent multiple myeloma) treated solely with radiotherapy (6,7). The goal of surgery is wide resection with free margins of normal tissue of at least 4 cm on all sides, in order to prevent local recurrence. Additionally, if any structures are attached to the bone (pleura, lung, pericardium, thymus, or diaphragm) their excision is recommended (1,6,7). In case of lesions smaller than 5 cm or high posterior defects smaller than 10 cm (where the scapula provides support and protection) there can be no need of reconstructive procedures, while in case of wide excision causing extensive chest wall defects (>10 cm posteriorly, >5 cm in any other sites, or located where the near the scapula tip) both bony reconstruction and soft tissue coverage are indispensable (6-8). In this setting, surgeons can cover the chest wall defects with prosthetic or biological (allo- or homograft) mesh and/or tissue flaps (8-13), based on their expertise and preferences (6). Indeed, reconstruction of the chest wall guarantees the preservation of respiratory function and chest mechanics associated to the protection of intrathoracic organs (6,7). Morbidity rate after chest wall reconstruction in our case was 32.3%, lower compared to the literature (6), this may be due to a careful selection of fit patients undergoing surgery. In major series reported in the literature and summarized in *Table 3*, 1-year OS rate ranged from 52% to 89%, 3-year OS rate from 45.6% to 65%, 5-year OS rate

Table 3 Major studies of PMCWTs

References	Number of patients	Age, years (range)	Males/females	Bony/soft/others	Reconstructions (yes/no)	Recurrence, n	1, 3, 5-year OS, %
Abdel Rahman AM, 2017	98	39 (25–52.3)	47/51	45/44/9	47/51	35	73.9, 45.6, 34.6
Lin GQ, 2015	50	NR	37/13	9/41/0	NR	NR	NR
Bagheri R, 2014	40	43.7 (11–86)	20/20	18/18/4	35/5	24	NR, 65, NR
Togashi K, 2014	17	50 (24–76)	12/5	11/6/0	10/7	2	NR
Maeda S, 2014	25	49 (15–73)	12/13	12/13/0	19/6	NR	NR
Hsu PK, 2006	31	59.9	21/10	9/22/0	NR	10	NR
Athanassiadi K, 2001	18	59 (33–78)	9/9	9/9/0	3/15	18	NR, NR, 33.3
Sabanathan S, 1997	49	53.2 (14–82)	22/27	22/27/0	36/13	NR	NR, NR, 68
King RM, 1986	71	46 (10–96)	33/38	24/44/3	NR	37	89, NR, 57
Threlkel JB, 1971	23	NR	NR	5/14/4	NR	NR	52.2, NR, 26
Our series	52	58 (2–85)	28/24	29/19/4	31/21	13	83.3, 69.9, 51.5

PMCWTs, primary malignant chest wall tumors; NR, not reported.

from 33.3% to 57% and 10-year OS rate from 17.4% to 68%. Our experience is in line with literature data. In our study, the independent predictors of better OS were the no need of prosthetic reconstruction and chondro-osseous tumor histological type. Indeed, these data are confirmed by analysis of the literature, where histological type represents an important independent prognostic factor (8,17,18). The absence of prosthetic reconstruction may reflect the small dimension of the resected lesion and a less aggressive tumor; indeed, also King and Colleagues found the extent of invasion of the tumor as an independent prognostic factor (17). The complete resection of the tumor represents the most important factor for survival according to Ito *et al.* (1), but in our case it did not impact on survival, perhaps this is due to the low numerosity of the uncompleted resection (R1 and R2) subgroup. Recurrence rates for PMCWTs reported in literature ranged from 25% to 100% (19–21), in line with our experience.

Conclusions

Surgical resection is the gold standard treatment in case of PMCWTs. A careful pre-operative selection of fit patients, especially in chondro-osseous subtype without prosthetic reconstruction leads to good survival outcomes with acceptable morbidity.

Acknowledgments

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

1. Ito T, Suzuki H, Yoshino I. Mini review: surgical management of primary chest wall tumors. *Gen Thorac Cardiovasc Surg* 2016;64:707–14.
2. Abdel Rahman ARM, Rahouma M, Gaafar R, et al. Contributing factors to the outcome of primary malignant chest wall tumors. *J Thorac Dis* 2017;9: 5184–93.
3. Cipriano A, Burfeind W Jr. Management of primary soft tissue tumors of the chest wall. *Thorac Surg Clin* 2017;27:139–47.
4. Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. Who classification of tumors of soft tissue and bone, 4th

- Edition, 2013.
5. Souza FF, de Angelo M, O'Regan K, et al. Malignant primary chest wall neoplasms: a pictorial review of imaging findings. *Clin Imaging* 2013;37:8-17.
 6. Smith SE, Keshavjee S. Primary chest wall tumors. *Thorac Surg Clin* 2010;20:495-507.
 7. Shah AA, D'Amico TA. Primary chest wall tumors. *J Am Coll Surg* 2010;210:360-6.
 8. Bagheri R, Haghi SZ, Kalantari MR, et al. Primary malignant chest wall tumors: analysis of 40 patients. *J Cardiothorac Surg* 2014;9:106.
 9. Sanna S, Brandolini J, Pardolesi A, et al. Materials and techniques in chest wall reconstruction: a review. *J Vis Surg* 2017;3:95.
 10. Stella F, Dell'Amore A, Dolci G, et al. Allogenic sternal transplant after sternectomy for metastasis of ovarian carcinoma. *Ann Thorac Surg* 2012;93:e71-2.
 11. Marulli G, Dell'Amore A, Calabrese F, et al. Safety and effectiveness of cadaveric allograft sternochondral replacement after sternectomy: a new tool for the reconstruction of anterior chest wall. *Ann Thorac Surg* 2017;103:898-905.
 12. Dell'Amore A, Cassanelli N, Dolci G, et al. An alternative technique for anterior chest wall reconstruction: the sternal allograft transplantation. *Interact Cardiovasc Thorac Surg* 2012;15:944-7.
 13. Tamburini N, Grossi W, Sanna S, et al. Chest wall reconstruction using a new titanium mesh: a multicenters experience. *J Thorac Dis* 2019;11:3459-66.
 14. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available online: <https://www.R-project.org/>, 2018.
 15. Therneau TM, Lumley T. Package 'survival.' Survival analysis Published on CRAN 2014.
 16. Calcagno V, de Mazancourt C. glmulti: an R package for easy automated model selection with (generalized) linear models. *J Stat Softw* 2010;34:1-29.
 17. Lin GQ, Li YQ, Huang LJ, et al. Chest wall tumors: diagnosis, treatment and reconstruction. *Exp Ther Med* 2015;9:1807-12.
 18. King RM, Pairolero PC, Trastek VF, et al. Primary chest wall tumors: factors affecting survival. *Ann Thorac Surg* 1986;41:597-601.
 19. Threlkel JB, Adkins RB Jr. Primary chest wall tumors. *Ann Thorac Surg* 1971;11:450-9.
 20. Athanassiasi K, Kalavrouziotis G, Rondogianni D, et al. Primary chest wall tumors: early and long-term results of surgical treatment. *Eur J Cardiothorac Surg* 2001;19:589-93.
 21. Togashi K, Yamato Y, Kitahara T. Resection of chest wall tumors. *Kyobu Geka* 2014;67:27-30.

doi: 10.21037/ccts.2019.11.08

Cite this article as: Bellini A, Ferrigno P, Comacchio GM, Rossi S, Cannone G, Lomangino I, Bellofiore G, Mammana M, Lorenzoni G, Azzolina D, Gregori D, Zuin A, Dell'Amore A, Rea F. Primary malignant chest wall tumors: surgical management and factors predicting survival. *Curr Chall Thorac Surg* 2019;1:20.